New Mountain Capital-backed Aceto completed the acquisition of a majority stake in Finar.

New Mountain Capital-backed Aceto, a global provider of differentiated specialty materials in life sciences and advanced technology end markets, completed the acquisition of a majority stake in Finar, manufacturer of high purity laboratory chemicals and pharmaceutical excipients. Financial terms were not disclosed. “We are excited to bring together Finar and Aceto to give customers of both companies more solutions to support their supply chains globally. With the Finar team’s help, we continue to strengthen our manufacturing expertise and expand our product offerings for the pharmaceutical, biopharmaceutical, and vaccine end markets,” Gilles Cottier, Aceto CEO.